Clinical Study
Clinical Results after High-Dose Intensity-Modulated Radiotherapy for High-Risk Prostate Cancer
Table 2
Patient’s characteristics for all patients and according to prescription group.
| | Characteristic | | Prescription group | | | | All () | 74R72 () | 76R74 () | 78R76 () |
| | Age (years) | 66 (41–79) | 62 (51–76) | 65 (53–75) | 66 (41–79) | | Followup (months) | 48 (24–132) | 60 (24–132) | 84 (24–108) | 45 (24–96) | | PSA level (ng/mL) | 19 (4–302) | 26 (8–150) | 20 (4–90) | 14 (4–302) | | Gleason score | | | | | | 2–6 | 49 (39) | 9 (43) | 11 (58) | 29 (34) | | 7 (3 + 4)/(4 + 3) | 37 (29) | 7 (33) | 5 (26) | 25 (29) | | 8–10 | 39 (31) | 5 (24) | 3 (16) | 31 (36) | | Unknown | 1 (1) | — | — | 1 (1) | | Tumor stage | | | | | | T1 | 17 (13) | 2 (10) | 4 (20) | 11 (12) | | T2 | 40 (32) | 9 (43) | 2 (11) | 29 (34) | | T3 | 60 (48) | 7 (33) | 12 (64) | 40 (48) | | T4 | 9 (7) | 3 (14) | 1 (5) | 6 (6) | | Node stage | | | | | | pN0 | 54 (43) | 9 (43) | 3 (16) | 42 (49) | | Androgen deprivation | | | | | | Yes | 116 (92) | 14 (67) | 17 (89) | 85 (99) | | No | 10 (8) | 7 (33) | 2 (11) | 1 (1) |
|
|
